In addition, our recent results showed that KCNB1 polymorphisms were associated with Tumor-Node-Metastasis (TNM) progression and treatment response and suggests that such polymorphisms as biomarkers of CRC outcomes, before and during chemotherapy process [17]. This evidence concerns the gene KCNB1 and neoplasm.